Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Archford Capital Strategies LLC

Archford Capital Strategies LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 33.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,737 shares of the medical research company's stock after selling 1,364 shares during the quarter. Archford Capital Strategies LLC's holdings in Thermo Fisher Scientific were worth $1,362,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth $25,000. Pillar Financial Advisors LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $30,000. Noble Wealth Management PBC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $35,000. Finally, Cassady Schiller Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 89.2% during the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after acquiring an additional 33 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. Royal Bank Of Canada decreased their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. UBS Group lowered their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Finally, Argus decreased their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $604.05.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $404.34 on Wednesday. The stock has a fifty day moving average price of $410.92 and a 200 day moving average price of $485.85. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The firm has a market capitalization of $152.64 billion, a P/E ratio of 23.72, a PEG ratio of 2.11 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the firm posted $5.11 EPS. The company's revenue was up .2% on a year-over-year basis. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.